2-{[3-Chloro-5-(trifluoromethyl)-2-pyridinyl]-sulfanyl}nicotinic acid

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-{[3-Chloro-5-(trifluoromethyl)-2-pyridinyl]-sulfanyl}nicotinic acid
• 英文别名: 2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]sulfanylpyridine-3-carboxylic acid
• 化学式: C₁₂H₆ClF₃N₂O₂S
• 分子量: 334.7
• InChiKey: VLGROHDCHOAOOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  88.4
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF<br/>[FR] MÉTHODES DE TRAITEMENT DE MALADIES ASSOCIÉES À LA XANTHINE OXYDASE AVEC DE L'ACIDE NIFLUMIQUE ET SES DÉRIVÉS
  申请人：BAYLOR COLLEGE MEDICINE

  公开号：WO2021188296A1

  公开（公告）日：2021-09-23

  Provided herein are methods of using niflumic acid and derivatives thereof for treating a disease or condition associated with elevated serum uric levels in a subject. The methods include administering to the subject an effective amount of a pharmaceutical composition as described herein. The disease or condition associated with elevated serum uric levels can include, for example, gout, hyperuricemia, or cardiovascular disease. Also provided herein are methods of reducing serum uric acid levels in a subject and methods for inhibiting xanthine oxidase activity in a cell. Novel pharmaceutical compositions are also provided herein. (I)